We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program
News

Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program

Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program
News

Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pharmalink AB Gains Exclusive License to Archimedes Pharma’s TARGIT® Technology for Nefecon® (Pl-56) Program"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Pharmalink AB has announced that it has gained an exclusive global license to Archimedes Pharma Ltd.’s TARGIT® drug delivery technology for use in its lead program, Nefecon® for the treatment of the kidney disease IgA nephropathy.

As part of the agreement, Pharmalink has also acquired from Archimedes Pharma certain specialized equipment and the technologies needed to manufacture TARGIT capsules for Nefecon for its ongoing clinical development program.

Pharmalink has paid Archimedes Pharma an undisclosed upfront payment for the license and other assets and will pay a royalty on the sales of Nefecon.

Today’s agreement follows a productive co-development program between Pharmalink and Archimedes Pharma that began in 2004 and saw Nefecon successfully complete an open Phase II trial evaluating efficacy and safety.

Pharmalink now assumes full control and responsibility for the further development of Nefecon.

Pharmalink’s Managing Director Johan Häggblad said, “We believe Nefecon has great potential as a new medicine for a currently poorly treated disease that can ultimately lead to renal failure. Our collaboration with Archimedes delivered very strong progress and having secured an exclusive license to TARGIT we look forward to continuing to drive the development of Nefecon and bringing an important new treatment option to patients.”

Archimedes Pharma’s Chief Executive Officer Jeffrey H. Buchalter said, “We are pleased that the license of our unique TARGIT drug delivery technology to Pharmalink will allow the development of Nefecon to progress. We will continue to have an interest in the advancement and success of Nefecon to address this unmet medical need.”

Archimedes retains all TARGIT rights outside the Nefecon areas of study.

Nefecon is an enteric formulation of a locally acting corticosteroid which down regulates the inflammatory process in the kidneys through suppression of the gut immune system.

It is delivered using the proprietary TARGIT drug delivery technology which enables the localized delivery of drugs to the lower small intestine or colonic regions of the gut.

The concept underlying Nefecon is a patented invention by Professors Bengt Fellström and Roger Hällgren at Uppsala University (Sweden).

Advertisement